Swiss pharmaceutical giant Roche on Wednesday said falling sales of COVID-19 tests and medicines will stop having a “material ...

Roche lowered its 2024 growth outlook in February as it continues to confront a drop-off in demand for its Covid-19 products ...

Roche confirmed ambitions to return to sales growth this year on a continued boost from eye drug Vabysmo, after first-quarter ...

Please subscribe to my Seeking Alpha Marketplace Service "Biotech Analysis Central", whereby you can subscribe to either my "Full Tier" at $399/yr or my "Basic Tier" service at $299/yr instead. If ...

The biotech's top-line dip can be traced to a loss of COVID-related revenues.

Roche first-quarter sales declined amid weak demand for Covid-19 products and currency headwinds but slightly beat analysts expectations. The Swiss pharmaceutical giant said Wednesday that sales ...

Among Big Pharma companies specifically, Gilead, Roche and Pfizer topped the list ... linked to their speed and efficacy in ...

Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line ...

When it comes to sharing ideas, how much does close proximity matter? A study by Maria Roche evaluates how knowledge spreads ...

Roche said falling COVID-19 sales will stop having a “material impact” on its business. Swiss pharmaceutical giant Roche on Wednesday said falling sales of COVID-19 tests and medicines will ...